Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4359394 | 0.79 | MEN1 (0.44) | HTR2CMEN1KMT2ALMNAHSD17B10 | |
| SCHEMBL19582587 | 0.75 | HIF1A (0.47) | MEN1KMT2ALMNAHSD17B10PLK4 | |
| Hydrochloric Acid SCHEMBL6196951 | 0.75 | HTR2C (0.33) | HTR2CHTR2AHTR2B | |
| SCHEMBL4809703 | 0.73 | MAOA (0.42) | MEN1KMT2ALMNAHSD17B10PLK4 | |
| SCHEMBL5945476 | 0.72 | DAPK3 (0.36) | HTR2CMEN1KMT2ALMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL7936771 | 0.72 | NOS3 (0.33) | HTR2CHTR2AHTR2B | |
| SCHEMBL7095283 | 0.71 | MAOA (0.41) | MEN1KMT2ALMNAHSD17B10PLK4 | |
| SCHEMBL9239604 | 0.71 | HTR2A (0.40) | HTR2CRXRALMNAMAOAHTR2A | |
| SCHEMBL8019722 | 0.69 | HIF1A (0.50) | MEN1KMT2AHSD17B10PLK4DAPK3 | |
| Hydrochloric Acid SCHEMBL7939254 | 0.68 | PLK4 (0.39) | HTR2CLMNAHSD17B10PLK4DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581209-A4 | NOVEL BENZOPYRAN ANALOGS AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-7396856-B2 | Benzopyran analogs and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2008-07-08 | — | — | US | disclosed |
| EP-1581209-A2 | NOVEL BENZOPYRAN ANALOGS AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2005-10-05 | — | — | EP | disclosed |
| US-20050209314-A1 | Novel benzopyran analogs and their use for the treatment of glaucoma | ALCON, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6933392-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-08-23 | — | — | US | disclosed |
| US-6884816-B2 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-26 | — | — | US | disclosed |
| WO-2004054572-A2 | NOVEL BENZOPYRAN ANALOGS AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2004-07-01 | — | — | WO | disclosed |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | MAY JESSE A (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2003-09-25 | — | — | US | disclosed |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181503-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HTR2C 2661/4885MEN1 2026/4885KMT2A 4251/4885 |
| US-20050209314-A1 | Novel benzopyran analogs and their use for the treatment of glaucoma | PGC, PDE3A, PTGIS | HTR2C 3277/4885MEN1 3605/4885KMT2A 4587/4885 |
| US-20030083346-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HTR2C 2661/4885MEN1 2026/4885KMT2A 4251/4885 |
| US-20030181504-A1 | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma | CYP11B1, CYP11B2, SQLE | HTR2C 2661/4885MEN1 2026/4885KMT2A 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.